一位50岁的澳大利亚女性通过Dupixent获得了持久的湿疹缓解，反映出全国过敏症状的上升趋势。 A 50-year-old Australian woman gained lasting eczema relief with Dupixent, reflecting a national rise in allergic conditions.

澳大利亚50岁的Jo Scaife在使用Dupixent药物后, 显著缓解了严重的湿疹, Jo Scaife, a 50-year-old Australian woman, found significant relief from severe eczema after starting Dupixent, a biologic injectable that targets immune system overreactions. 在经历了数十年痛苦的耀斑、类固醇依赖和近乎致命的健康危机之后,治疗稳定了她的皮肤,消除了对类固醇的需求,并恢复了她的生活质量。 After decades of painful flare-ups, steroid dependency, and near-fatal health crises, the treatment stabilized her skin, eliminated the need for steroids, and restored her quality of life. 她的经验表明,过敏性疾病增加幅度更大,现在每三个人中就有一个人受到过敏性疾病的影响——比2007年的20%有所增加——与环境压力、极端气候和增加的过敏性有关。 Her experience reflects a broader rise in allergic diseases, with eczema now affecting one in three people—up from 20% in 2007—linked to environmental stressors, climate extremes, and increased allergens. 去年,对像MooGoo公司那样的敏感皮肤产品的需求猛增近50%。 Demand for sensitive-skin products like those from MooGoo has surged nearly 50% in the past year. 专家建议采取医疗指导、一贯的皮肤护理和夏季防范措施,如矿物防晒霜和避免高温以控制症状。 Experts recommend medical guidance, consistent skincare, and summer precautions such as mineral sunscreen and avoiding peak heat to manage symptoms.